Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
November 26, 2025 | Intelligent Commercialisation, artificial intelligence
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
As health and life sciences companies prepare for launch, teams often face the same challenge: data lives in silos. Omnichannel engagement data, field insights, and clinical indicators sit in separate systems – making it difficult to form a connected view of readiness or identify the levers that will most influence launch success.
InConcert™ unites these fragmented datasets to help commercial and medical leaders answer the questions that matter most:
- Which HCPs are showing early interest or unmet need?
- Where are we under- or over-investing across channels?
- How is our field and MSL activity likely to impact uptake?
- What indicators point to the strongest early launch opportunities?
By combining proprietary and client-owned data into one intelligent suite, InConcert™ transforms uncertainty into foresight – helping teams model scenarios, anticipate challenges, and activate strategies with clarity and confidence.
The full picture of commercial performance
InConcert™ integrates omnichannel, field, and clinical behavior data through an LLM-powered interface that enables intuitive, natural-language querying.
Guided by embedded data scientists and cross-functional experts from across Inizio, users can interrogate their data in real time – moving seamlessly from insight to action.
“InConcert™ helps clients bring their data into focus – turning scattered signals into a clear view of launch readiness,” said Mary-Kate McGarry, Chief Strategy & Innovation Officer, Inizio.
“When teams can see where physicians are most responsive, how field activity drives uptake, and where investment will have the greatest impact, they can make every launch decision with greater insight and confidence.”
A connected intelligence solution built for the pivotal pre-launch moment
At this stage of the lifecycle, success depends on understanding how behavior, communication, and clinical context intersect. InConcert™ combines four core data layers that, together, provide an unparalleled pre-launch vantage point:
- Omnichannel intelligence: More than 25M hours of HCP engagement data reveal where interest is building, which messages resonate, and which needs remain unmet.
- Field performance insight: Over 200 brand meeting analyses uncover how in-field activity shapes perception and influence, informing targeting and deployment strategy.
- Clinical foresight: U.S. and EU modeling of real-world evidence connects clinical signals to commercial outcomes – helping teams understand where market readiness is strongest.
- Predictive engagement: AI-driven models trained on longitudinal datasets forecast behavioral shifts, guiding investment toward the highest-impact channels and content.
Together, these layers create a continuously learning system – one that adapts to each therapy area and market, giving teams a real-time view of where and how to act.
Leading the future of Intelligent Commercialization™ with InConcert™
By uniting three critical assets, InConcert™ positions Inizio at the forefront of Intelligent Commercialization™.
- Proprietary data and infrastructure: Decades of integrated datasets spanning engagement, scientific, and commercial domains.
- A connective AI backbone: A modular, LLM-powered platform that makes complex data easy to query, interpret, and operationalize.
- Embedded expertise: Access to specialists from across Inizio – whose insights are both built into the models and available on demand – ensuring every interpretation is grounded in scientific and strategic rigor.
Fast to activate and easy to scale, InConcert™ can be deployed within 10–14 weeks, with flexible pilot options that integrate quickly into existing systems and launch workflows.
“Every InConcert™ deployment starts with a client challenge,” said Jamie Avallone, Chief Data Officer, Inizio Evoke.
“Whether it’s identifying high-value targets or validating go-to-market assumptions, InConcert™ gives teams the answers they need – turning complex data into clear, confident launch decisions.”
With more than 700 pharma and biotech partnerships, Inizio helps clients unlock the full potential of their data – transforming fragmented insights into the connected intelligence that drives confident, high-impact launches.
Learn more about InConcert™ or get in touch with one of our experts today.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Infographic: The vaccine opportunity in Asia
As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...
Webinar: What next for biosimilars?
Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST
Understanding the Patient Journey
The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme. Technology...
Case Study: Oncology diagnostic biomarker landscaping study
The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...
Research Partnership publishes 2016 Living with RA reports
Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.
Article: The Art of Storytelling in Pharma Market Research
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director
Video: Immuno-oncology therapies
Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price...
The challenges of conducting effective pharmaceutical market research in emerging markets
Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets
“Most eye-catching” agency Pegasus scoops the ‘EMEA Healthcare PR Consultancy of the Year’ at Sabre Awards
Pegasus wins the prestigious “EMEA Healthcare PR Consultancy of the Year” award at the recent Sabre Awards in Berlin, organised by The Holmes Report.
Research Partnership appoints Director and Head of Business Analytics, North America
Tom has been appointed a Director in our Philadelphia office. He has over 25 years’ experience in healthcare research and has an extensive background in both quantitative and qualitative research,...